BioCorRx
BioCorRx Inc. (OTC: BICX) is a healthcare company focused on developing and delivering innovative treatment solutions for addiction and substance use disorders, combining pharmacological and behavioral health interventions into a comprehensive treatment approach. According to its website at biocorrx.com, the company offers the BioCorRx Recovery Program — a comprehensive treatment protocol for alcohol use disorder and opioid use disorder that combines naltrexone implant therapy with a proprietary counseling and behavioral health support component. BioCorRx's integrated treatment approach reflects the company's conviction that effective addiction treatment requires addressing both the neurochemical and behavioral dimensions of substance use disorders simultaneously, rather than relying on pharmacotherapy or counseling alone.
BioCorRx's treatment platform, described at biocorrx.com, centers on its BICX104 extended-release naltrexone implant — a subcutaneous implant that delivers sustained, consistent levels of naltrexone over an extended period, providing continuous pharmacological support for patients in recovery without requiring daily oral medication compliance. The company believes that extended-release naltrexone delivery eliminates one of the most significant barriers to effective pharmacotherapy for addiction — patient non-adherence to daily oral medication regimens — while also providing a more consistent therapeutic drug level that avoids the peaks and troughs associated with daily dosing. BioCorRx pairs this pharmacological intervention with its proprietary behavioral health program, which provides patients with structured counseling, peer support, and relapse prevention education designed to address the psychological and social dimensions of addiction recovery.
BioCorRx is pursuing FDA approval for its BICX104 extended-release naltrexone implant through the regulatory pathway for new drug applications, conducting clinical studies designed to demonstrate the safety, efficacy, and pharmacokinetic profile of its implant formulation. According to biocorrx.com, the company has established a network of licensed healthcare providers and treatment centers that deliver the BioCorRx Recovery Program using currently available naltrexone formulations while the BICX104 implant advances through clinical development. BioCorRx's combination of an innovative extended-release naltrexone delivery platform, integrated behavioral health treatment protocol, and growing network of licensed treatment providers positions it as a differentiated participant in the substance use disorder treatment market at a time of growing national urgency around addressing the opioid and alcohol addiction crisis.